Kura OncologyKURA
About: Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
Employees: 142
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
94% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 36
28% more call options, than puts
Call options by funds: $1.2M | Put options by funds: $939K
17% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 41
3% more funds holding
Funds holding: 179 [Q3] → 184 (+5) [Q4]
4.7% less ownership
Funds ownership: 108.11% [Q3] → 103.41% (-4.7%) [Q4]
57% less capital invested
Capital invested by funds: $1.61B [Q3] → $686M (-$921M) [Q4]
60% less funds holding in top 10
Funds holding in top 10: 5 [Q3] → 2 (-3) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
JMP Securities Reni Benjamin 20% 1-year accuracy 8 / 40 met price target | 329%upside $28 | Market Outperform Reiterated | 29 Apr 2025 |
HC Wainwright & Co. Joseph Pantginis 20% 1-year accuracy 81 / 415 met price target | 514%upside $40 | Buy Reiterated | 28 Apr 2025 |
UBS David Dai 8% 1-year accuracy 1 / 13 met price target | 115%upside $14 | Buy Maintained | 6 Mar 2025 |
JMP Securities Reni Benjamin 19% 1-year accuracy 8 / 43 met price target | 329%upside $28 | Market Outperform Reiterated | 6 Feb 2025 |
Wedbush Robert Driscoll 4% 1-year accuracy 2 / 47 met price target | 452%upside $36 | Outperform Maintained | 6 Feb 2025 |
Financial journalist opinion
Based on 5 articles about KURA published over the past 30 days









